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Abstract
BACKGROUND: Poor cognitive performance is associated 
with high vascular risk. However, this association is only 
investigated in elderly. As neuropathological changes precede 
clinical symptoms of cognitive impairment by several decades, 
it is likely that cognitive performance is already associated with 
vascular risk at middle-age.
OBJECTIVES: To investigate the association of cognitive 
performance with treatable vascular risk in middle-aged and 
old persons.
DESIGN: Longitudinal study with three measurements during 
follow-up period of 5.5 years.
SETTING: City of Groningen, the Netherlands.
PARTICIPANTS: Cohort of 3,572 participants (age range, 35-82 
years; mean age, 54 years; men, 52%).
EXPOSURE: Treatable vascular risk as defined by treatable 
components of the Framingham Risk Score for Cardiovascular 
Disease at the first measurement (diabetes mellitus, smoking, 
hypercholesterolemia and hypertension).
MEASUREMENTS: Change in cognitive performance during 
follow-up. Cognitive performance was measured with Ruff 
Figural Fluency Test (RFFT) and Visual Association Test (VAT), 
and calculated as the average of the standardized RFFT and 
VAT score per participant.
RESULTS: The mean (SD) cognitive performance changed 
from 0.00 (0.79) at the first measurement to 0.15 (0.83) at second 
measurement and to 0.39 (0.82) at the third measurement 
(Ptrend<0.001). This change was negatively associated with 
treatable vascular risk: the change in cognitive performance 
between two measurements decreased with 0.004 per one-point 
increment of treatable vascular risk (95%CI, -0.008 to 0.000; 
P=0.05) and with 0.006 per one-year increment of age (95%CI, 
-0.008 to -0.004; P<0.001).
CONCLUSIONS: Change in cognitive performance was 
associated with treatable vascular risk in persons aged 35 years 
or older.
Key words: Cognitive performance, treatable vascular risk, 
longitudinal analysis, cardiovascular disease, preventing cognitive 
impairment.
Introduction
Several studies have shown that poor cognitive performance is associated with vascular risk factors in persons aged 60 years or older (1). As 
neuropathological changes start several decades prior to 
the clinical expression of cognitive impairment (2), it is 
likely that cognitive performance is already associated 
with vascular risk factors at middle-age. However, 
vascular risk factors in middle-aged persons often 
are only marginally elevated if considered separately. 
Nevertheless they result in a clearly increased vascular 
risk if considered together (3-6), which may contribute 
to the onset of neurodegenerative changes in the brain 
(7). Therefore, it is essential to know whether cognitive 
performance is associated with a high vascular risk in 
middle-aged persons.             
V a s c u l a r  r i s k  i s  u s u a l l y  e s t i m a t e d  w i t h 
multicomponent risk scores that predict an individual’s 
risk of a vascular event within the next years (3-6). 
These vascular risk scores are largely based on 
age. However, although age is a major vascular risk 
factor, it is not amenable to treatment. For effective 
prevention of cognitive impairment it is essential to 
know whether cognitive performance is associated with 
treatable vascular risk based on treatable components 
like, for example, diabetes mellitus, hypertension and 
hypercholesterolemia. Up till now, three longitudinal 
studies have found a negative association of cognitive 
performance with treatable vascular risk independent 
of age (8-10). However, one study included a relatively 
small sample of 235 men aged 60 years or older (8), 
whereas the two other studies mainly included even 
older persons from the same source population (the 
Alzheimer’s Disease Centers) (9, 10). Furthermore, in 
these three studies, the treatable vascular risk was based 
on a stroke-specific risk score and did not include the risk 
of cardiac or peripheral vascular events (4). Therefore, 
it is still unclear whether cognitive performance is 
associated with general treatable vascular risk, and not 
only with stroke-specific risk. Finally, the association 
between cognitive performance and treatable vascular 
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risk is not yet investigated in middle-aged persons since 
current data are only available for elderly (8-10). 
Therefore, this longitudinal study aims to investigate 
the association of cognitive performance with treatable 
(general) vascular risk independent of age over a follow-
up period of six years in both middle-aged as old persons. 
Methods
Study design
This study was part of the Prevention of REnal 
and Vascular ENd-stage Disease (PREVEND) cohort. 
The PREVEND study is a prospective cohort study 
investigating the natural course of microalbuminuria 
and its association with renal and cardiovascular disease. 
Details of the PREVEND study have been described 
elsewhere (11, 12). Briefly, at baseline 8,592 participants 
aged 28-75 years were selected from inhabitants of the 
city of Groningen (Netherlands) based on their urinary 
albumin excretion. These participants completed the 
baseline survey in 1997-1998 and were followed over 
time. Surveys included assessment of demographic 
and vascular risk factors, and measurements of 
haematological and biochemical parameters. Cognitive 
function tests were introduced at the third survey (2003-
2006) and repeated at the fourth survey (2006-2008) and 
fifth survey (2008-2012). A total of 3,601 participants 
completed two to three measurements of cognitive 
performance.
The PREVEND study was approved by the medical 
ethics committee (METc) of University Medical Center 
Groningen, Groningen, the Netherlands, and conducted 
in accordance with the guidelines of the Helsinki 
declaration. All participants gave written informed 
consent.
Cognitive performance
Cognitive performance was measured as a composite 
score of two tests: the Ruff Figural Fluency Test (RFFT) 
and the Visual Association Test (VAT). The RFFT is 
generally seen as a measure of executive function but 
provides also information regarding planning, divergent 
thinking and the ability to shift between different 
cognitive tasks. The RFFT requires the participants to 
draw as many designs as possible within a set time limit 
while avoiding repetitions of designs. The main outcome 
of the RFFT is the total number of unique designs, which 
range from 0 points (worst score) to 175 points (best 
score) (13). The RFFT is sensitive to changes in cognitive 
performance in both young and old persons (13, 14).
The VAT is a brief learning task that is designed 
to detect memory impairment including anterograde 
amnesia. The test consists of six drawings of pairs of 
interacting objects. The participant is asked to name 
each object and, later, is presented with one object from 
the pair and asked to name the other object. The lowest 
(worst) score is 0 points, the highest (best) score is 12 
points (15).
To create a composite cognitive score, the raw RFFT 
and VAT scores at each measurement were standardized 
to z-scores (based on the mean and standard deviation 
of each test at the first measurement) and subsequently 
averaged.
Treatable vascular risk
Treatable vascular risk was based on the components 
of the Framingham Risk Score for Cardiovascular 
Disease (FRS-CD) that are amenable to treatment: 
diabetes mellitus (yes/no), current smoker status (yes/
no), systolic blood pressure (mmHg), total cholesterol 
(mmol/l), HDL cholesterol (mmol/l) and use of blood 
pressure lowering drugs (yes/no). The FRS-CD is 
designed to predict the risk of a new cardiovascular, 
cerebrovascular or peripheral vascular event within the 
next ten years. This model was validated for persons aged 
30-74 years without vascular history (3). 
A higher treatable vascular risk score is associated with 
a higher risk of a new vascular event: the lowest score is 
-5 (10-year risk <1%), and the highest score is 21 (10-year 
risk >30%) (3).
Measurements of treatable vascular risk 
components
Data on the treatable vascular risk were obtained in 
the third survey of the PREVEND study at the same visit 
at which the first measurement of cognitive performance 
was done: total cholesterol, HDL-cholesterol and glucose 
were measured with fasting blood tests. Diabetes mellitus 
was defined as a fasting glucose ≥7.0 mmol/L (126 mg/
dl) or a non-fasting glucose ≥11.0 mmol/L (200 mg/
dl) or the use of glucose-lowering drugs. Smoking was 
defined as current smoker based on self-report. Systolic 
blood pressure was automatically measured (Dinamap) 
in a supine position during ten minutes and reported as 
the average of the two last measurements. Data on actual 
drug use were obtained from the InterAction DataBase 
that comprised pharmacy-dispending data from regional 
community pharmacies (16).
Covariates
Demographic factors were measured at the first 
measurement. Data on age, gender and educational 
level were obtained from a questionnaire. Educational 
level was divided into four groups: primary school (0 
to 8 years of education), lower secondary education (9 
to 12 years of education), higher secondary education 
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(13 to 15 years of education), and university (≥16 years 
of education). Because the effect of vascular risk on 
cognitive function is possibly modified by APOE ε4 
carriership (17), APOE ε4 genotype was included as a 
covariate. Participants were categorized as APOE ε4 
carriers (allele combinations e2/e4 or e3/e4 or e4/e4) or 
noncarriers (allele e2/e2 or e2/e3 or e3/e3).
Statistical analysis
Parametric data are presented as mean and standard 
deviation (SD) and nonparametric data as median and 
interquartile range (IQR). Differences were tested by 
independent-samples t test or, if appropriate, Mann-
Whitney U test. Differences between paired observations 
were tested by paired-samples t test or, if appropriate, 
Wilcoxon signed-rank test. Differences in proportion 
were tested by Chi-Square test.  Trends across 
measurements were analyzed by ANOVA for parametric 
data and by Kruskal-Wallis H test for nonparametric 
data.
The longitudinal association of cognitive performance 
with the treatable vascular risk was investigated by 
linear multilevel analysis (linear mixed model analysis). 
Cognitive performance was the dependent variable. 
Treatable vascular risk at the first measurement was the 
independent variable. The analysis included the data 
of all participants who completed the cognitive tests on 
at least two measurements. Consecutive measurement 
(1, 2, or 3) was the lowest level and participant the 
highest level. Interaction between the treatable vascular 
risk and consecutive measurement was investigated 
by entering the product term treatable vascular 
risk x consecutive measurement into the regression 
model. Interaction between the treatable vascular 
risk and APOE ε4 carriership was tested by entering 
treatable vascular risk x APOE ε4 carriership into the 
model. Adjustment was made for age, educational 
level, consecutive measurement and interaction age x 
consecutive measurement. To study the effect of the 
separate components of treatable vascular risk, a 
similar regression model was built with all separate 
components (Supplement). In all models, the variables 
cognitive performance, consecutive measurement, age 
(years) and treatable vascular risk (points) were entered 
as continuous variables. Educational level and APOE 
ε4 carriership were entered as categorical variables. 
The level of statistical significance was set at 0.05. The 
linear multilevel analyses were performed using MLwiN 
Version 2.29 (Centre for Multilevel Modelling, University 
of Bristol, Bristol, UK) (18), the other analyses were 
performed using IBM SPSS Statistics 22.0 (IBM, Amonk, 
NY).
Sensitivity analyses
Various a priori-defined analyses were performed. 
First, the analyses were limited to persons aged 35-74 
years without vascular history, because the FRS-CD 
was only validated in this age group (3). Second, to 
investigate the generalizability of our findings, analyses 
were repeated with two other risk scores based on the 
treatable components of the Framingham Risk Score 
for Coronary Heart Disease (FRS-CHD) and the SCORE 
risk system (5,6). Third, the analyses were repeated after 
exclusion of all APOE ε2 carriers (allele combinations ε2/
ε2, ε2/ε3 and ε2/ε4) because the APOE ε2 allele appears 
to reduce the risk of Alzheimer’s disease (19). Finally, 
the analyses were repeated in a subset of the PREVEND 
cohort, the Groningen Random Sample, which had a 
similar prevalence of microalbuminuria (8%) and other 
cardiovascular risk factors as the general population (20). 
Results
Study population
Overall, 3,601 participants completed the cognitive 
tests at multiple measurements: 2,431 (68%) participants 
at three measurements and 1,170 (32%) participants at 
two measurements. Eighteen (0.5%) participants were 
excluded because their educational level was not known 
and three (0.1%) participants because their age was 
younger than 35 years and their number too small to form 
a separate age group. Eight (0.2%) persons were excluded 
because of missing data on treatable vascular risk. Thus, 
the total study population included 3,572 persons with a 
mean (SD) age of 54 (11) years, 52% were men and 96% of 
Western-European descent (Table 1).
Longitudinal course of cognitive performance 
and treatable vascular risk
The mean (SD) total follow-up time was 5.5 (0.7) years. 
The mean (SD) cognitive performance of the total study 
population changed per consecutive measurement from 
0.00 (0.79) at the first measurement to 0.15 (0.83) at second 
measurement and to 0.39 (0.82) at third measurement 
(Ptrend<.001). The change in cognitive performance 
per consecutive measurement was most clear in the 
age groups 35 to 44 years, 45 to 54 years, and 55 to 64 
years (Table 2). Treatable vascular risk ranged from -5 
to +17 points with a mean (SD) of 2 (4) points at the 
first measurement. Except for the age group 35 to 44 
years, treatable vascular risk did not change statistically 
significantly per consecutive measurement (Table 2).
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Table 1. Characteristics of the study population at the 
first measurement (baseline)
All
n (%) 3,572 (100)
Age (years), mean (SD) 54 (11)
Age groups, n (%)
   35-44 years 824 (23)
   45-54 years 1182 (33)
   55-64 years 889 (25)
   65-74 years 534 (15)
   ≥75 years 143 (4)
Gender, n (%)
   Men 1867 (52)
  Women 1705 (48)
Educational level, n (%)
   Primary school 396 (11)
   Secondary lower education 930 (26)
   Secondary higher education 968 (27)
   University 1278 (36)
Cardiovascular history, n (%) 160 (5)
   Cardiac event 133 (3)
   Cerebrovascular event 24 (1)
   Peripheral vascular event 3 (1)
Cardiovascular risk factors
   Hypertension, n (%) 1222 (34)
   Diabetes mellitus, n (%) 197 (6)
   Smoker, n (%) 799 (22)
   Systolic blood pressure (mmHg), mean (SD) 125 (17)
   Total cholesterol (mmol/L), mean (SD) 5.36 (1.04)
   HDL-cholesterol (mmol/L), mean (SD) 1.41 (0.38)
   Non-HDL-cholesterol (mmol/L), mean (SD) 3.94 (1.02)
Blood pressure lowering drugs, n (%) 827 (23)
APOE ε4 carriership*, n (%) 943 (26)
Abbreviations: HDL, high-density lipoprotein; SD, standard deviation; * APOE 
ε4 carriership included the allele combinations ε2/ε4, ε3/ε4 and ε4/ε4.
Longitudinal change in cognitive performance 
and treatable vascular risk
Longitudinal change in cognitive performance was 
dependent on treatable vascular risk: the change in 
cognitive performance was negatively associated with 
treatable vascular risk (Figure 1). The mean change 
in cognitive performance between the first and third 
measurement was 0.46 (95%CI, 0.37 to 0.55; P<.001) in 
persons with the lowest treatable vascular risk whereas 
it was 0.28 (95%CI, 0.08 to 0.47; P=.006) in persons with 
the highest treatable vascular risk. The association 
between cognitive performance and treatable vascular 
risk was confirmed by multilevel analysis. Adjusted 
for age, educational level, consecutive measurement 
and interaction age x consecutive measurement, 
the multilevel regression model did not only show a 
statistically significant effect for treatable vascular risk 
(B-coefficient, -0.011; 95%CI, -0.019 to -0.003; P=.01) but 
also for the interaction between treatable vascular risk 
and consecutive measurement (Table 3). The change 
in cognitive performance between two measurements 
decreased with 0.004 per one-point increment of treatable 
vascular risk (B-coefficient, -0.004; 95%CI, -0.008 to 0.000; 
P=.05). This is comparable to the decrease in change in 
cognitive performance between two measurements per 
one-year increment of age (B coefficient, -0.006; 95%CI, 
-0.008 to -0.004; P<.001) (Table 3).
Effect of APOE ε4 carriership
The effect of treatable vascular risk on cognitive 
performance was not modified by APOE ε4 carriership 
as there was no statistically significant interaction 
between treatable vascular risk and APOE ε4 carriership: 
B-coefficient for treatable vascular risk, -0.009 (95%CI, 
-0.019 to 0.001; P=.07), for APOE ε4 carriership, 0.003 
(95%CI, -0.048 to 0.054; P=.91), and for the interaction 
treatable vascular risk x APOE ε4 carriership, -0.003 
(95%CI, -0.015 to 0.009; P=.62).
Figure 1. Mean cognitive performance per measurement 
dependent on the treatable vascular risk at first 
measurement. Bars represent 95% confidence intervals. 
Cognitive performance was measured as a composite 
score of two tests (z-score): the Ruff Figural Fluency Test 
(RFFT) and the Visual Association Test (VAT) (13,15). 
Treatable vascular risk is based on the components of 
Framingham Risk Score for Cardiovascular Disease 
that are amenable to treatment and included diabetes 
mellitus, current smoker status, total cholesterol, HDL-
cholesterol, systolic blood pressure and use of blood 
pressure lowering drugs (3)
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Association with separate components of 
treatable vascular risk
Cognitive performance was not only associated 
with treatable vascular risk but also with different 
components of treatable vascular risk. Adjusted for age, 
gender, educational level, consecutive measurement 
and interaction age x consecutive measurement, the 
full multilevel regression model showed that cognitive 
performance was negatively associated with diabetes 
mellitus (B coefficient, -0.11; 95%CI, -0.19 to -0.02; P=.01), 
current smoker (B-coefficient, -0.08; 95%CI, -0.13 to -0.04; 
P<.001) and hypertension (B-coefficient, -0.05; 95%CI, 
-0.10 to 0.00; P=.03), and positively associated with 
HDL-cholesterol (B-coefficient, 0.08; 95%CI, 0.02 to 0.13; 
P=.005). However, the longitudinal change in cognitive 
performance was not dependent on any of the separate 
components of treatable vascular risk because there was 
no statistically significant interaction between separate 
components and consecutive measurement (P=.20) 
(Supplement).
Sensitivity analyses
Essentially similar results were found if the analyses 
of the association of cognitive performance with the 
treatable vascular risk were limited to persons aged 35 
to 74 years without vascular history. If the analyses were 
repeated with treatable vascular risks based on treatable 
components of FRS-CHD or SCORE as independent 
variables, the negatively association between cognitive 
performance and treatable vascular risk was also 
found. If the analyses were repeated after exclusion of 
all APOE ε2 carriers, there was no interaction between 
treatable vascular risk and APOE ε4 carriership. Finally, 
the association of cognitive performance with treatable 
vascular risk was also found in the Groningen Random 
Sample (Supplement). 
Table 2. Change in cognitive performance* and treatable vascular risk† across measurements per age group
Age (years) Variable Measurement P trend
First Second Third
35-44 Cognitive performance, z-score 0.41 (0.71) 0.67 (0.68) 0.90 (0.64) <.001
Treatable vascular risk, points 1 (3) 0 (3) 1 (3) .02
45-54 Cognitive performance, z-score 0.16 (0.73) 0.30 (0.71) 0.55 (0.65) <.001
Treatable vascular risk, points 2 (4) 2 (4) 2 (4) .09
55-64 Cognitive performance, z-score -0.17 (0.73) -0.04 (0.76) 0.15 (0.73) <.001
Treatable vascular risk, points 3 (4) 3 (4) 3 (3) .83
65-74 Cognitive performance, z-score -0.52 (0.68) -0.46 (0.73)  -0.40 (0.77) .07
Treatable vascular risk, points 4 (3) 4 (3) 4 (3) .13
≥75 Cognitive performance, z-score -0.72 (0.69) -0.75 (0.78) -0.62 (0.76) .56
Treatable vascular risk, points 5 (3) 4 (3) 5 (3) .42
All values are noted as mean (SD). Abbreviations: SD, standard deviation; * Cognitive performance was measured as a composite score of two tests (z-score): the 
Ruff Figural Fluency Test (RFFT) and the Visual Association Test (VAT) (13,15); † Treatable vascular risk is based on the components of Framingham Risk Score for 
Cardiovascular Disease that are amenable to treatment and included diabetes mellitus, current smoker status, total cholesterol, HDL-cholesterol, systolic blood pressure 
and use of blood pressure lowering drugs (3). 
Table 3. Longitudinal association of cognitive performance* on the treatable vascular risk†: multilevel linear analysis
Model 1§ Model 2|| Model 3{
B 95%CI P B 95%CI P B 95%CI P
Age (years) -0.020 -0.022 to -0.018 <.001 -0.018 -0.020 to -0.016 <.001 -0.018 -0.020 to -0.016 <.001
Educational level (vs. primary school)
Secondary lower education 0.20 0.13 to 0.26 <.001 0.19 0.13 to 0.26 <.001 0.19 0.13 to 0.26 <.001
Secondary higher education 0.40 0.33 to 0.47 <.001 0.38 0.32 to 0.45 <.001 0.38 0.32 to 0.45 <.001
University 0.68 0.61 to 0.75 <.001 0.65 0.58 to 0.72 <.001 0.65 0.58 to 0.72 <.001
Measurement‡ 0.50 0.43 to 0.56 <.001 0.50 0.44 to 0.56 <.001 0.48 0.42 to 0.54 <.001
Age x measurement‡ -0.006 -0.008 to -0.004 <.001 -0.006 -0.008 to -0.004 <.001 -0.006 -0.008 to -0.004 <.001
Treatable vascular risk† -0.018 -0.024 to -0.012 <.001 -0.011 -0.019 to -0.003 .01
Treatable vascular risk† x measurement‡ -0.004 -0.008 to 0.000 .05
Abbreviations: B, unstandardized B-coefficient; CI, confidence interval; * Cognitive performance was measured as a composite score of two tests (z-score): the Ruff Figural 
Fluency Test (RFFT) and the Visual Association Test (VAT) (13,15); † Treatable vascular risk is based on the components of Framingham Risk Score for Cardiovascular 
Disease that are amenable to treatment and included diabetes mellitus, current smoker status, total cholesterol, HDL-cholesterol, systolic blood pressure and use of blood 
pressure lowering drugs (3); ‡ Consecutive measurement; § For model 1: -2*log likelihood 16864.08; || For model 2: -2*log likelihood 16822.30; { For model 3: -2*log 
likelihood 16817.67.
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Discussion
In this large community-based study, cognitive 
performance was negatively associated with treatable 
vascular risk over a follow-up period of almost six 
years in persons aged 35 to 82 years old. As reported 
previously (12), cognitive performance increased across 
the measurements probably due to the repeated exposure 
to the cognitive tests. However, the change in cognitive 
performance was dependent on treatable vascular risk 
and was lower if treatable vascular risk was higher. In 
addition, our data suggested that the effect of treatable 
vascular risk on cognitive performance was comparable 
to the effect of age.
Our results were comparable to the findings of the 
National Aging Study (NAS) and the two studies from 
the National Alzheimer Coordinating Center (NACC) 
cohort (8-10). In all studies, poor cognitive performance 
was associated with high treatable vascular risk 
independent of age. However, our study differs from 
these studies in study population, duration of follow-
up, APOE ε4 carriership and type of treatable vascular 
risk score. Whereas the other studies included specific 
populations of elderly people, our study showed this 
association in population that comprised both middle-
aged and old persons. Furthermore, in the NAS and 
NACC studies the negative association of cognitive 
performance with treatable vascular risk was found 
over an average follow-up period of three years (8-10). 
Notably, our study adds that this association persisted 
after a period of almost six years. Comparable to one 
NACC study (10), our study also showed that the effect of 
treatable vascular risk factors on cognitive performance 
was not changed by APOE ε4 carriership whereas the two 
other studies did not evaluate the interaction of APOE ε4 
carriership with treatable vascular risk (8, 9). Moreover, 
in our study the treatable vascular risk was based on a 
general vascular risk score and not on a stroke-specific 
risk score which was used in the NAS and NACC studies 
(8-10). Therefore, vascular risk management programmes 
based on general vascular risk may not only prevent 
cardiac, cerebrovascular and peripheral vascular events 
but possibly also cognitive impairment. In addition, our 
findings from a study population of middle-aged and old 
persons support the hypothesis that the start of vascular 
risk management at late-life may be too late for effective 
prevention of cognitive impairment and dementia (21, 
22).
Interestingly, our data suggested that the effect of 
treatable vascular risk on cognitive performance was 
comparable to the effect of age. This is in agreement with 
the finding of the NAS study that the association between 
cognitive performance and treatable vascular risk was 
almost as strong as that between cognitive performance 
and age (8). As a result, it may be estimated that one-
point decrement of treatable vascular risk per year can 
probably gain one-year in cognitive age. One-point 
decrement of treatable vascular risk can be achieved by 10 
mmHg reduction in systolic blood pressure or 1 mmol/L 
reduction in total cholesterol (3). These target values are 
usually achieved in clinical practice and randomized 
controlled trials (RCTs) (23, 24). Smoking cessation even 
results in three-points decrement of treatable vascular 
risk (3). Several studies did not only show that smoking 
is a risk factor for cognitive impairment, but also that 
smoking cessation decreased the risk of cognitive 
impairment to the risk of persons who have never 
smoked (25). So, smoking cessation is a good preventive 
measure and may compensate cognitive decline that 
occurs in three-years increment of age. Thus, a relevant 
decrease in vascular risk is probably feasible and is like to 
gain several years in cognitive age.
Recently, it was observed that over the past decades 
management of vascular risk factors has coincided 
with a decline in the prevalence of dementia (26). Our 
findings supported that vascular risk management may 
not only result in a lower incidence of cardiovascular 
disease but possibly also in a lower incidence of 
cognitive impairment and dementia. However, up till 
now, various RCTs have found inconsistent results 
about the effect of treatment of vascular risk factors 
on cognitive performance (27). Only the Syst-Eur 
trial suggested a protective effect of antihypertensive 
treatment on dementia in contrast to other trials (27, 
28). Similarly, intensified treatment of diabetes mellitus 
or cholesterol lowering treatment had no effect on 
cognitive performance in other large trials such as the 
ADVANCE study and the PROSPER trial (24, 27, 29). It 
is generally acknowledged that these negative findings 
may be explained by the use of a relatively insensitive 
cognitive test or short follow-up period (27). The 
FINGER, preDIVA and MAPT trials did not have these 
shortcomings (30-32). The FINGER trial showed that a 
multidomain intervention including treatment of vascular 
risk factors during two years could improve or maintain 
cognitive performance. However, the effect of treatment 
of vascular risk factors on cognitive performance per 
se was unclear as the multidomain intervention also 
included cognitive training (30). On the other hand, 
the preDIVA trial did not show a positive effect of 
the multidomain vascular intervention on cognitive 
performance, possibly because there was a similar 
reduction in cardiovascular risk in the intervention and 
control group (31). Similarly, the MAPT study did not 
found a difference in 3-year cognitive decline between 
control group and the multidomain intervention 
including physical activity, cognitive training and 
nutritional advice (32). Moreover, the trials included only 
old persons who were at risk for cognitive impairment 
(30-32). Considering our findings, starting vascular risk 
management in old age or risk groups may be too late 
for effective prevention of cognitive impairment and 
dementia (21, 22).
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Some limitations of this study have to be noted. First, 
our study had an observational design whereas it is 
generally acknowledged that observational studies may 
give results that differ from subsequent RCTs on the 
same questions, and may overestimate treatment effects 
(33). However, RCTs with duration of four years or even 
longer seem hardly feasible due to high costs and the 
ethics of not treating vascular risk factors for a long time 
in placebo group (34, 35). Therefore, observational studies 
with a long follow-up period are still essential to gain 
more insight in the consequence of increased vascular 
risk in middle-age. Second, cognitive performance was 
measured with two cognitive tests in this study which 
may not evaluate all cognitive domains. However, the 
RFFT measures a wide range of different cognitive 
abilities such as initiation, planning, divergent reasoning, 
and the ability to switch between different tasks (13). In 
addition, because of its wide score range, the RFFT is not 
limited by a ceiling or floor effect and, thereby, sensitive 
to subtle changes in cognitive performance in young and 
old persons (13, 14). Furthermore, the VAT was added 
as a measure of memory (15). Although both tests are 
dependent on language and relatively specific measures 
of frontal network functions, semantic and episodic 
memory, these two tests combined reflect the cognitive 
domains commonly affected by Alzheimer’s disease and 
vascular dementia. Finally, in our study the cognitive 
performance increased across the measurements probably 
due to repeated exposure to the tests resulting in a 
practice effect (12). Practice effects appear in most, if 
not all, cognitive tests which assess various cognitive 
domains like memory, attention and executive functions 
(36). Practice effects can be ascribed to different factors 
such as memory of previous responses and learning test 
strategies, and could explain that people improve or 
maintain their cognitive performance despite a cognitive 
decline (36). However, in our study the association of 
cognitive performance with treatable vascular risk was 
adjusted for repeated consecutive measurement by 
entering the variable consecutive measurement and the 
interaction age x consecutive measurement in the model.
Despite these limitations, the present study also 
has several strengths. Our study was based on a large 
community-based cohort and included a large number 
of both middle-aged and elderly people whereas other 
longitudinal studies used selected populations of elderly 
(8-10). In addition, by using a (general) vascular risk 
score we explored the synergistic effects of vascular risk 
factors instead of focusing on a single risk factor. Risk 
scores have the advantage that multiple separate risk 
factors are weighted to generate optimal overall risk 
estimation for individual patients. Additionally, they 
yield a single variable that is the optimal estimate for 
overall cardiovascular burden, which limits the number 
of variables in small studies or multivariate analyses 
(3-6). Moreover, vascular risk scores are particularly 
valuable to identify increased vascular risk in middle-
aged people because in this age group vascular risk 
factors often are only marginally elevated if considered 
separately but result in a clearly increased vascular risk if 
considered together (3-6).
In conclusion, in this large community-based cohort 
change in cognitive performance was associated with 
treatable vascular risk in both middle-aged and old 
people. Our data support the hypothesis that the start 
of vascular risk management at late-life may be too late 
for effective prevention of cognitive impairment and 
dementia. 
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